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Abstract
Background & Aims—Following radiofrequency ablation (RFA), patients may experience 
recurrence of Barrett’s esophagus (BE) after complete eradication of intestinal metaplasia (CEIM). 
Rates and predictors of recurrence after successful eradication are poorly described.
Methods—We used the U.S. RFA Registry, a nationwide registry of BE patients receiving RFA, 
to determine rates and factors that predicted recurrence of IM. We assessed recurrence by Kaplan-
Meier analysis for the overall cohort and by worst pretreatment histology. Characteristics 
associated with recurrence were included in a logistic regression model to identify independent 
predictors.
Results—Among 5521 patients, 3728 had biopsies ≥12 months after initiation of RFA. Of these, 
3169 (85%) achieved CEIM, and 1634 (30%) met inclusion criteria. Average follow-up was 2.4 
years after CEIM. IM recurred in 334 (20%), and was non-dysplastic or indefinite for dysplasia in 
86% (287/334); the average length of recurrent BE was 0.6 cm. In Kaplan-Meier analysis, more 
advanced pretreatment histology was associated with an increased yearly recurrence rate. 
Compared to patients without recurrence, patients with recurrence were more likely, based on bi-
variate analysis, to be older, have longer BE segments, be non-Caucasian, have dysplastic BE 
before treatment, and require more treatment sessions. In multivariate analysis, likelihood for 
recurrence was associated with increasing age and BE length, and non-Caucasian race.
Conclusion—BE recurred in 20% of patients followed for an average of 2.4 years after CEIM. 
Most recurrences were short segments and were non-dysplastic or indefinite for dysplasia. Older 
age, non-Caucasian race, and increasing length of BE length were all risk factors. These risk 
factors should be considered when planning post-RFA surveillance intervals.
Keywords
esophageal cancer; risk factors; adenocarcinoma; EAC
Barrett’s esophagus (BE) affects 1-2% of the general population and is associated with an 
increased risk of esophageal adenocarcinoma (EAC), a cancer with increasing incidence 
over the last four decades.1-5 BE is defined as an endoscopically visible metaplastic change 
of the esophagus in which the squamous epithelium is replaced by columnar mucosa 
exhibiting goblet cells, also termed specialized intestinal metaplasia (IM). Endoscopic 
ablative therapy is a treatment modality aimed at eradicating dysplasia and intestinal 
metaplasia to prevent the development of EAC.6
Radiofrequency ablation (RFA) has been shown to be safe and effective in treating BE, with 
substantial rates of complete eradication of dysplasia (CED) and intestinal metaplasia 
(CEIM) and decreased rates of progression to EAC in the setting of dysplasia.7-9 However, 
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the long-term durability of the neosquamous epithelium remains poorly characterized. The 
few studies reporting durability of CED and CEIM are limited by small sample sizes, and 
most have short duration of follow-up. Also, these studies have unclear generalizability, as 
they were conducted at tertiary care centers.10-15
The aim of this study was to investigate the rate of recurrence of intestinal metaplasia after 
successful CEIM in a nationwide, multicenter registry of patients treated with RFA. We also 
sought to define risk factors for recurrence of BE after successful ablation.
Methods
U.S. RFA Patient Registry
The U.S. RFA Patient Registry is a multi-center collaboration reporting processes and 
outcomes of care for patients treated with RFA for BE at 148 institutions in the U.S. (113 
community-based, 35 academic-affiliated). The registry was developed as a research tool to 
monitor clinical outcomes after RFA using the HALO Ablation Systems (Covidien, GI 
Solutions, Sunnyvale, CA), and is funded by Covidien. The registry does not mandate 
protocols for care, but provides a suggested protocol for treatment and follow-up of patients 
with BE. All physicians participating (n=320) either used Western institutional review board 
(IRB) approval, or obtained IRB approval through their respective institutions.
Registry Patient Eligibility
Patients were enrolled from July, 2007 to July, 2011. Patients were eligible for inclusion if: 
(1) they had endoscopic evidence of columnar metaplasia in the tubular esophagus with 
accompanying biopsies demonstrating intestinal metaplasia, and (2) received RFA for BE. 
Subjects were classified using standardized histological grading, including non-dysplastic 
BE (NDBE), indefinite for dysplasia (IND), low-grade dysplasia (LGD), high-grade 
dysplasia (HGD), or carcinoma, subclassified as intramucosal carcinoma (IMC), and 
invasive esophageal adenocarcinoma (EAC).16, 17 Patients who had received one or more 
RFA treatments prior to enrollment had collection of retrospective data, with subsequent 
prospective collection for ensuing visits. Patients who had not yet undergone treatment were 
prospectively enrolled in the study.
Data Collection and Record Retention
Information collected in the registry includes demographic data, histology prior to treatment, 
endoscopic findings, number of treatment sessions, ablation outcomes, and complications. 
All data were recorded on standardized case report forms. Data were collated into a central 
electronic database, with real-time monitoring for logic checks and consistency. Data were 
analyzed by investigators in the clinical epidemiology program at UNC (T32 DK07634), 
who had complete access to the data.
Treatment Protocol
Data from previous clinical trials were given as a guideline for treatment and follow-up 
protocol. However, because this is a registry study, physicians could deviate from the 
protocols, depending on specific patient requirements and physician preferences. The 
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suggested treatment protocol provided to physician investigators has been previously 
described.18
At enrollment, each patient was interviewed and a Baseline Encounter Form, which 
collected medical history information and demographics,was completed. The standardized 
protocol included medical therapy with twice-daily PPIs to minimize any baseline 
inflammatory changes of the esophageal mucosa and decrease acid reflux prior to and 
throughout RFA treatment, unless the patient had a documented history of antireflux 
surgery.
At the initial visit, patients were treated with one of two ablation devices: the HALO360 
circumferential ablation system or the HALO90 focal ablation system. The decision as to 
initial treatment modality was based on the burden of disease (Barrett’s segments of >3 cm 
are generally best treated with the circumferential catheter), as well as operator preference. 
Recommended treatment protocols were based on previously published data.9
Follow-Up Protocol
Recommendations for the first follow-up visit, which was 2-3 months after treatment 
initiation, included additional circumferential or focal RFA treatment for any visible residual 
BE, depending on the extent of the disease. If no visible BE was observed, four-quadrant 
biopsies every cm were recommended throughout the length of the pre-treatment BE. If 
these biopsies were clear of BE on pathologic review, the patients entered the surveillance 
phase. Initial surveillance was recommended at 3 months for HGD or 6 months for NDBE, 
IND, or LGD. If follow-up biopsies revealed IM or dysplasia, recurrent treatment with RFA 
was recommended.
Adverse events were reported using standardized forms and terminology. Each site also 
complied with reporting guidelines for their institution regarding reporting adverse events to 
their IRB and FDA under the MDR reporting regulation in 21 C.F.R. Part 803.
Outcomes and Statistical Analysis
For this analysis, our cohort was restricted to subjects who achieved CEIM and had at least 
one post-CEIM biopsy session. CEIM was defined as an esophageal biopsy session in which 
no biopsy demonstrated intestinal metaplasia, occurring at least 12 months after initial 
treatment. Recurrence was defined as any biopsy from the esophagus demonstrating 
intestinal metaplasia during surveillance. The primary outcome was recurrence of IM. 
Additionally, to assess differences in outcome using a more stringent definition of CEIM, 
we also calculated recurrence of IM in patients who had 2 consecutive biopsy sessions with 
CEIM.
Statistical analysis was performed using Stata software (version 12.0; StataCorp LP, College 
Station, TX). For descriptive statistics, mean and standard deviations were reported for 
continuous variables, and percentages were reported for categorical variables. Outcomes are 
described for all patients, as well as stratified by pre-ablation histology. We used log-rank 
test to evaluate for differences by worst pre-treatment histology, and compared rates of 
recurrence and time to recurrence by pre-treatment histology using Pearson’s chi-square test 
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and one-way analysis of variance, respectively. We performed Kaplan-Meier analysis to 
determine rates of recurrence of IM. Patients with and without recurrence were compared 
using parametric statistics for demographic data, pre-treatment EGD findings (length of BE, 
presence of dysplasia, history of fundoplication) and number of treatments necessary to 
achieve CEIM. Characteristics associated with recurrence on bivariate analysis (p<0.20) 
were included in a logistic regression model to identify independent predictors of 
recurrence. The model was reduced using the likelihood ratio test.
Results
A total of 5,521 patients with BE were enrolled in the U.S. RFA Patient Registry and were 
treated with RFA. Among these patients, 3,728 had biopsies obtained ≥12 months following 
initiation of RFA therapy. Of these, 3,169 (85%) achieved CEIM on biopsies obtained ≥12 
months after initial treatment, and 559 (15%) had such biopsies taken but did not achieve 
CEIM. Of the 3,169 who achieved CEIM and had biopsies taken ≥12 months after initial 
treatment, 1,634 (52%) had at least 1 additional biopsy session after the biopsy session 
demonstrating CEIM (Figure 1), and could be analyzed for BE recurrence. Baseline 
characteristics of the 1,634 patients who met inclusion criteria for analysis are reported in 
Table 1. The mean age was 61.7 years, 74% were male, and 93% were Caucasian. Among 
the 1,634 patients included, 66% (1,079) were enrolled prospectively and 34% (555) were 
enrolled with some retrospective data. Pre-treatment histology included: 668 (41%) NDBE, 
114 (7%) IND, 323 (20%) LGD, 416 (25%) HGD, 113 carcinomas (92 (6%) IMC; 21 (1%) 
EAC). The mean pre-treatment BE length was 4.0 cm. On average, patients were observed 
for 2.4 ± 1.3 years (3983 total years) after CEIM with 4.3 ± 1.8 biopsy sessions performed 
after CEIM was achieved (7066 total).
Among the 1,634 patients in our study population, recurrence of IM occurred in 334 (20%). 
An additional 28 subjects (2%) had empiric retreatment with RFA for suspected recurrence 
based on endoscopic appearance, without histological confirmation. Mean length of BE at 
recurrence was 0.6 cm. When we applied the alternative, more stringent definition of CEIM 
(2 consecutive biopsy sessions without intestinal metaplasia) the rate of recurrence of IM did 
not markedly change (supplemental table 1). With this more stringent definition, recurrence 
was seen in 16% of patients (97/604), with a mean follow-up of 1.8 ± 1.0 years (1077 total 
years; supplemental figures 1 and 2).
In patients undergoing endoscopic surveillance following CEIM, an analysis of durability 
was performed using Kaplan-Meier estimation (Figure 2a). Subjects with baseline dysplasia 
demonstrated increased recurrence rates compared to those without dysplasia (p < 0.001) 
(Figure 2b).
To assess the relationship of pre-treatment histology to the risk of recurrence, recurrence 
rates were stratified by pre-treatment histology (table 2). More advanced pre-treatment 
histology was associated with increased yearly recurrence rates (7% NDBE; 11% LGD; 
10% HGD; 12% IMC; 19% EAC; p = 0.0003), although the rates of recurrence among 
LGD, HGD and IMC were similar. We also assessed the relationship between pre-treatment 
histology and histology at the time of BE recurrence (table 3). Overall, histology at 
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recurrence was non-dysplastic or IND in 287/334 (86%). Of patients with recurrence, 94% 
(314/334) showed histology identical to or less severe than their baseline histology. In total, 
6% (20/334) of patients with recurrence (1.2% of the overall study population) had 
histologic disease progression (i.e., histologic grade of recurrence worse than pre-treatment 
grade). No patient with baseline NDBE or IND progressed to carcinoma. Four patients with 
LGD, IND or NDBE before treatment progressed to HGD. Two patients with LGD and six 
patients with HGD before treatment progressed to carcinoma, with all of these being IMC. 
The annual rate of IM recurrence was 9% among all 1634 patients included in the analysis, 
regardless of baseline histology.
Compared to patients without recurrence, patients with recurrence were more likely in 
bivariate analysis to: 1) be older (63.3 vs. 61.3yrs, p = 0.003); 2) have longer BE (4.8 vs. 3.8 
cm, p < 0.0001); 3) be of non-Caucasian race (93% vs. 96%, p 0.03); 4) have dysplastic BE 
(IND or worse) prior to treatment (64% vs. 58%, p = 0.03); and, 5) have more total RFA 
treatment sessions (3.1 vs. 2.8, p = 0.004). In multivariate analysis, non-Caucasian race (OR 
2.00, 95% CI 1.20 – 3.34), length of BE (1.10 per cm, 1.06 – 1.15), and age (1.02 per year, 
1.01 – 1.03) were independent predictors of IM recurrence (Table 4). Likelihood for 
recurrence was not influenced by sex, pre-treatment dysplasia, treatment with EMR, or 
treatment at an academic versus community-based practice in multivariable analysis. 
Additionally, although total number of treatment sessions was associated with increased risk 
of recurrence in bivariate analysis, number of RFA sessions was not an independent 
predictor of IM recurrence in multivariable analysis.
Discussion
In the largest reported cohort of patients treated with RFA for BE, we investigated the rate 
of IM recurrence, and predictors for recurrence of IM. Of the 1,634 subjects included in our 
analysis, 1,300 (80%) maintained CEIM and 334 (20%) had recurrence of IM. Histology at 
time of recurrence was NDBE or IND in the vast majority (86%). However, 6% (20/334) 
had histological disease progression at time of recurrence. The total length of BE at the time 
of recurrence (mean of 0.6 cm) was markedly less than baseline (mean of 4.0 cm). More 
advanced pre- treatment histology was associated with an increased yearly recurrence rate. 
Although the Kaplan-Meier analysis and the bivariate analysis suggested that patients with 
dysplastic BE prior to treatment were more likely to have recurrence, after controlling for 
multiple variables, including BE length, this association was insignificant in the multivariate 
model. The likelihood of recurrence after successful treatment with RFA was increased in 
those who are older, not Caucasian, and had longer BE segments. These results support the 
need for long-term surveillance endoscopy even in patients successfully treated for BE with 
RFA.
Multiple studies have reported the durability of RFA, with differing results. In a recent 
systematic review and meta-analysis, Orman et al. found that these studies reported an IM 
recurrence rate of approximately 13%. In this analysis, higher-quality studies had lower 
recurrence rates (11%) than lower-quality studies (17%).19 Recent prospective cohorts 
demonstrate the range of outcomes reported. For example, Phoa and colleagues reported 
excellent results, with 90% of 54 patients with neoplastic BE treated with RFA still clear of 
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IM at 5 years.20 Conversely, patients in the UK National Halo RFA Registry experienced 
relatively high recurrence rates, with 38% of the 335 patients with neoplastic BE 
demonstrating recurrence of BE at 12 months.21 Our research differs from these prior 
studies by including patients with a range of pre-treatment histology, as well as patients 
from both academic and community centers, making our results more generalizable. 
Additionally, our cohort is the largest to report outcomes associated with radiofrequency 
ablation.
The cause for the considerable heterogeneity in the reported durability of ablation is unclear. 
Some of the variability may be due to diverse patient populations, different follow-up time 
periods, and variability in treatment and surveillance protocols. While the results reported in 
this registry suggest a higher rate of recurrence than some of the studies noted above, this 
may in part be a reflection of the non-standardized nature of the treatment protocols, or the 
lack of inclusion/exclusion criteria used in clinical trials to select optimal patient 
populations. Additionally, since biopsy protocols after CEIM could not be mandated, some 
of these “recurrences” may represent incomplete initial treatment. A lack of consensus 
definition of CEIM may also contribute to the discrepancies in durability outcomes seen in 
the RFA studies. There is variability in defining CEIM using one negative biopsy session 
compared to two negative biopsy sessions. In order to understand the impact of alternative 
definitions of CEIM, we analyzed our cohort using both candidate definitions. Interestingly, 
we found little difference in recurrence rates based on definition of CEIM (20% using one 
negative biopsy session compared to 16% using two negative biopsy sessions). The most 
preferable definition for CEIM remains unclear.
Although several studies have reported the durability of RFA, there are very limited data on 
the predictors of recurrence of BE after successful CEIM. Prior studies in general lacked 
statistical power to assess predictors of recurrence. Vaccaro and colleagues demonstrated 
that patients with recurrent IM had longer BE segments at baseline than those who remained 
free of IM (median, 4 cm vs. 2 cm; p=0.03), similar to our finding.22 Orman et al. published 
data on recurrence of CEIM in patients with either baseline dysplastic BE or IMC treated 
with RFA and found no statistical difference in a variety of clinical, endoscopic, and 
treatment variables as predictors of recurrence.10 Unfortunately, this study was limited by a 
small number of overall recurrences and multivariate analysis could not be performed. The 
above data likely suffer from type II error due to relatively small sample sizes and the few 
patients who suffered recurrence. In contrast, given the large cohort in the present study, we 
were able to perform both bivariate and multivariate analysis to determine a number of 
predictors of recurrence which can be used to guide clinical practice.
Our study has limitations that must be considered when interpreting our data. Our study was 
strictly observational and we could not mandate care paradigms. It is possible that 
physicians did not follow the recommended biopsy protocol. Additionally, TMN staging for 
cancers was not provided in the registry. Given the size and nature of our study, there was 
no central lab for re-interpretation of pathological specimens, thus interobserver variation 
almost certainly introduces misclassification into our study.23, 24 However, nationwide, few 
clinicians have access to highly specialized labs for biopsies, and our results are likely a 
better reflection of real-world outcomes than tertiary center reports. While the majority of 
Pasricha et al. Page 7






















the patients (66%) in our cohort were enrolled prospectively, the retrospective portion of this 
study also makes misclassification error possible. However, assessment of our primary 
outcome in subjects with solely prospective data collection shows no meaningful difference 
between recurrence rates (19.8% with only prospective data vs. 20.4% for all subjects). 
Furthermore, random esophageal biopsies performed after CEIM is attained may under-
estimate the prevalence of residual or recurrent IM, especially sub-squamous IM. 
Additionally, the 20% IM recurrence rate may be a low-end estimation given our protocol 
did not require that routine biopsies be taken at the gastro-esophageal junction. We also 
excluded the 2% of patients that had empiric RFA re-treatment without histologic 
confirmation since we are unable to confirm whether these patients had recurrent metaplasia. 
Finally, some subjects identified as having IM recurrence may have instead had incomplete 
initial eradication of IM and would thus actually be failures of initial therapy, rather than 
true recurrences.
Our study has several strengths. We report the largest cohort of patients treated with RFA 
for BE and the largest reported study assessing durability and predictors of CEIM. This 
study used the U.S. RFA Patient Registry, which includes 320 physician participants from 
148 institutions, both community-based and academic-affiliated. The diversity of practice 
settings and variety of procedural volumes improves the external validity of our results. 
Additionally, study definitions were a priori, and data were collected in a standardized 
fashion.
Our findings have implications on future endoscopic surveillance intervals following 
ablation. Given that the mean time to IM recurrence in patients with NDBE or IND at 
baseline was 2.1 and 1.9 years, respectively, and that none of these patients progressed to 
cancer, patients with NDBE or IND at pre-treatment do not appear to require initial 
surveillance endoscopies at intervals <2 years. On the other hand, more frequent 
surveillance may be warranted in patients who are older, and had longer pre-treatment 
segments. Additionally, non-Caucasians were found to have increased risk of IM recurrence. 
Although the reasons for these associations remain unclear, it is possible that elderly people 
have more prolonged exposure to carcinogens and are more likely to accumulate somatic 
mutations, while a longer pre-treatment segment may be a marker for more severe acid 
exposure and injury. Perhaps non-Caucasians are at increased risk because of a genetic 
predisposition to recurrence or from socio-economic factors that may affect follow-up 
appointments, treatment, or medication adherence.
In conclusion, after successful treatment of BE with RFA, the majority of patients 
demonstrate durability of squamous epithelium. However, regardless of the definition of 
disease eradication used, approximately 1/5th of patients followed for a mean of 2.4 years 
had recurrent BE. When BE did recur, most recurrences were of short length and either non-
dysplastic or indefinite for dysplasia. The likelihood for recurrence after successful 
treatment with RFA was increased in those who are older, not Caucasian, and had longer BE 
segments. Additionally, more severe baseline histology predicts recurrence in Kaplan-Meier 
estimates, although this finding is equivocal when controlled for other patient 
characteristics. These data suggest that continued surveillance following treatment is 
necessary to detect recurrent BE. Additionally, we suggest attenuation of surveillance 
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intervals based on these data. Finally, we have identified specific factors that predict 
recurrence of IM, which can be used to better stratify risk and personalize follow-up 
surveillance.
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Flow diagram of patient enrollment
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Figure 2a. Recurrence free survival in all study subjects (n=1634)
Kaplan-Meier plot of IM recurrence among patients who achieved CEIM after RFA, overall.
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Figure 2b. Recurrence free survival study subjects grouped by pre-treatment histology (n=1613)
Kaplan-Meier plot of IM recurrence among patients who achieved CEIM after RFA, with 
pre-treatment histology nondysplasic BE, low-grade dysplasia (LGD), and high-grade 
dysplasia (HGD). P = 0.001 between dysplastic and non-dysplastic BE.
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Table 1
Baseline characteristics of patients under endoscopic surveillance following CEIM
n=1634
Age, mean years ± SD 61.7 ± 10.9






Other/not identified 47 (3)
Pre-Treatment histology, n (%)
Nondysplastic BE 668 (41)
Indefinite Dysplasia 114 (7)
Low-grade dysplasia 323 (20)
High-grade dysplasia 416 (25)
Carcinoma 113 (7)
Time of Observation in years, mean ± SD 2.4 ± 1.3
Length of BE segment, mean cm ± SD 4.0 ± 3.1
Fundoplication before treatment, n (%) 95 (6)
EMR before RFA, n (%) 212 (13)
RFA treatment sessions, mean ± SD 2.9 ± 1.7
Circumferential RFA session, mean ± SD 0.7 ± 0.9
Focal RFA sessions, mean ± SD 2.2 ± 1.5
Biopsy sessions performed after CEIM, mean ± SD 4.3 ± 1.8
Treated at academic medical center, n (%) 536 (33)
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Table 2


























1.9 ± 1.1 2.1 ± 1.2 1.9 ± 1.0 1.8 ± 1.0 1.7 ± 1.1 1.5 ± 0.9 1.4 ± 0.8 0.11
Recurrences/
year 9 % 7 % 10 % 11 % 10 % 12 % 19 % 0.0003
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Table 3




















334(20) 269 (81) 18 (5) 19 (6) 15 (4) 13 (4) 0
NDBE




25 (22) 21 (84) 2 (8) 1 (4) 1 (4) -- --
LGD
(N=323) 70 (22) 57 (81) 6 (9) 4 (6) 1 (1) 2 (3) --
HGD
(N=416) 93 (22) 64 (69) 4 (4) 10 (11) 9 (10) 6 (6) --
IMC
(N=92) 21 (23) 16 (76) -- -- 1 (5) 4 (19) --
EAC
(N=21) 6 (29) 1 (17) 2 (33) 1 (17) 1 (17) 1 (17) --
Color coding: Green, less severe histology at time of IM recurrence; Yellow, same pre and post histology at time of IM recurrence; Red, more 
severe histology at time of IM recurrence.
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Table 4
Multivariate Analysis of Predictors of Recurrence
Odds Ratio (95% CI) Base Model Reduced Model
Age, per year 1.02 (1.01 – 1.03) 1.02 (1.01 – 1.03)
Not Caucasian 2.09 (1.24 – 3.51) 2.00 (1.20 – 3.34)
Male gender 1.16 (0.86 – 1.57) --
Length of BE segment, per cm 1.09 (1.04 – 1.14) 1.10 (1.06 – 1.15)
Pre-treatment fundoplication 1.42 (0.87 – 2.32) --
Pretreatment dysplastic BE 1.08 (0.81 – 1.44) --
Treated with EMR before RFA 0.95 (0.64 – 1.41) --
Total RFA sessions, per treatment 1.04 (0.96 – 1.12) --
Treatment at community practice 1.04 (0.78 – 1.38) --
Reduced Model includes age, race, and length of BE segment.
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